Role for Class I histone deacetylases in multidrug resistance

Experimental Cell Research

Volumn 318, Issue 3, 2012, Pages 177-186

  Xu, Yichun ^a,b   Jiang, Zijing ^a   Yin, Peihao ^c   Li, Qi ^c   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Shanghai Biochip Limited Corporation   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Histone deacetylases; Multidrug resistance; P gp; Sp1

Indexed keywords

FLUOROURACIL; GLYCOPROTEIN P; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; MESSENGER RNA; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NUCLEAR FACTOR Y; OXALIPLATIN; PROTEIN P300; TRANSCRIPTION FACTOR SP1; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CELL STRAIN HCT116; CHEMOSENSITIVITY; CHROMATIN STRUCTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84855854154     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.11.010     Document Type: Article

References (37)

1. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13:477-483.
2. Piekarz R., Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 2004, 10:2289-2298.
3. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21:2672-2681.
4. Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E., Blagosklonny M.V., Bates S.E. P21-dependent G(1)arrest with downregulation of cyclin D1and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 2000, 83:817-825.
5. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
6. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., Davidsen S.K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310:529-536.
7. Senese S., Zaragoza K., Minardi S., Muradore I., Ronzoni S., Passafaro A., Bernard L., Draetta G.F., Alcalay M., Seiser C., Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol. 2007, 27:4784-4795.
8. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14:1669-1677.
9. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
10. Harms K.L., Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007, 67:3145-3152.
11. Gotttesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
12. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
13. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-7523.
14. Jones P.M., George A.M. The ABC transporter structure and mechanism: perspectives on recent research. Cell. Mol. Life Sci. 2004, 61:682-699.
15. Pakunlu R.I., Wang Y., Tsao W., Pozharov V., Cook T.J., Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 2004, 64:6214-6224.
16. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 2001, 58:931-959.
17. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., Reinhold W., Guo Y.P., Kruh G.D., Reimers M., Weinstein J.N., Gottesman M.M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137.
18. Deeley R.G., Cole S.P. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006, 580:1103-1111.
19. Tabe Y., Konopleva M., Contractor R., Munsell M., Schober W.D., Jin L.H., Tsutsumi-Ishii Y., Nagaoka I., Igari J., Andreeff M. Up-regulation of MDR1and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 2006, 107:1546-1554.
20. Kim Y.K., Kim N.H., Hwang J.W., Song Y.J., Park Y.S., Seo D.W., Lee H.Y., Choi W.S., Han J.W., Kim S.N. Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem. Biophys. Res. Commun. 2008, 368:959-964.
21. Keshelava N., Davicioni E., Wan Z., Ji L., Sposto R., Triche T.J., Reynolds C.P. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J. Natl. Cancer Inst. 2007, 99:1107-1119.
22. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. 1996, 93:5705-5708.
23. Mareel M., Leroy A. Clinical cellular and molecular aspects of cancer invasion. Phys. Rev. 2003, 83:337-376.
24. Levites Y., Youdim M.B., Maor G., Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclearfactor-kappa B (NF-kappa B) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 2002, 63:21-29.
25. Zhang J., Shen Y.L., Liu J.W., Wei D.Z. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem. Pharmacol. 2005, 69:407-414.
26. Rudner J., Elsaesser S.J., Muller A.C., Belka C., Jendrossek V. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis. Biochem. Pharmacol. 2010, 79:10-20.
27. Abbaszadegan M.R., Futscher B.W., Klimecki W.T., List A., Dalton W.S. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994, 54:4676-4679.
28. Sonneveld P., Wiemer E. Inhibitors of multidrug resistance. Curr. Opin. Oncol. 1997, 9:543-548.
29. Jin S., Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 1998, 18:4377-4384.
30. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 1997, 40(Suppl.):S3-S8.
31. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39:361-398.
32. Lania L., Majello B., Luca P.D. Transcriptional regulation by the Sp family proteins. Int. J. Biochem. Cell Biol. 1997, 29:1313-1323.
33. Takane H., Kobayashi D., Hirota T., Kigawa J., Terakawa N., Otsubo K., Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 2004, 311:1179-1187.
34. Daschner P.J., Ciolino H.P., Plouzek C.A., Yeh G.C. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res. Treat. 1999, 53:229-240.
35. Marilyn M.M., Smith D.E. A signal transduction pathway for activation of the MDRl promoter involves the proto-oncogene c-ruf kinase. J. Biol. Chem. 1993, 21:15347-15350.
36. Caretti G., Salsi V., Vecchi C., Imbriano C., Mantovani R. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J. Biol. Chem. 2003, 278:30435-30440.
37. Song C.Z., Keller K., Chen Y., Stamatoyannopoulos G. Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity. J. Mol. Biol. 2003, 329:207-215.